Targeting FLT3 to treat leukemia
Introduction: Approximately 23% of acute myeloid leukemia (AML) patients younger than 60 years of age carry a mutation in the transmembrane domain of the FMS-like tyrosine kinase-3 (FLT3) gene (FLT3/internal tandem duplications [ITD]). In normal karyotype AML, the presence of a FLT3/ITD mutation is...
Sábháilte in:
| Príomhchruthaitheoirí: | , |
|---|---|
| Formáid: | Revisão |
| Teanga: | Béarla |
| Foilsithe / Cruthaithe: |
2014
|
| Rochtain ar líne: | https://doi.org/10.1517/14728222.2014.960843 |
| Clibeanna: |
Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|